Skip to content
Open access

Real‐World Clinical Outcomes and Corticosteroid Tapering in Telitacicept‐Based Therapy for Ocular Myasthenia Gravis: An Exploratory Analysis by Prior Treatment History

Oct 2026 · Brain and Behavior · Vol 16 · 0 citations · 32 references
Medicine

Abstract

ABSTRACT Introduction Ocular myasthenia gravis (OMG) is an autoantibody‐mediated disease characterized by extraocular muscle weakness. Telitacicept has shown potential in treating autoimmune diseases, but its efficacy and corticosteroid‐tapering outcomes in OMG remain unexamined. Methods This retrospective, multicenter study evaluated the efficacy and corticosteroid‐tapering outcomes of telitacicept in 19 OMG patients (11 with refractory OMG and eight with newly/reinitiated treatment OMG). The primary endpoint was the proportion of patients achieving minimal symptom expression (MSE) within 6 months. Secondary endpoints included changes in Myasthenia Gravis Activities of Daily Living (MG‐ADL) scores and reductions in daily prednisone dosage, cumulative response rate (CRR), and short‐term tolerability. Results Following 6 months of telitacicept treatment, 68.42% of the overall cohort achieved MSE, with the median MG‐ADL score significantly decreasing from 3.00 to 0.00 (p < 0.0001). Daily prednisone dosage substantially decreased: the median daily prednisone dose fell from 20.00 to 5.00 mg (p < 0.0001), and 84.21% of patients received prednisone at ≤5 mg/day at month 6. All patients met the predefined initial response criterion within 5 weeks. The refractory and newly/reinitiated treatment groups achieved final MSE rates of 72.7% and 62.5%, respectively, and both groups showed significant reductions in prednisone dependence. This cohort had no serious adverse events. Conclusion In this exploratory cohort, telitacicept‐based therapy may represent a promising option for OMG, with favorable clinical outcomes, substantial prednisone dose reduction, and acceptable short‐term tolerability in patients with different prior treatment histories. Further prospective controlled studies are warranted.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.